REGNÂ – Regeneron Pharmaceuticals, Inc.
REGN — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
3.24
Margin Of Safety %
11
Put/Call OI Ratio
1.12
EPS Next Q Diff
3.62
EPS Last/This Y
3.43
EPS This/Next Y
1.7
Price
649.67
Target Price
838.23
Analyst Recom
1.71
Performance Q
-16.95
Upside
121.1%
Beta
0.29
Ticker: REGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-21 | REGN | 747.32 | 0.98 | 2.54 | 36726 |
| 2026-04-23 | REGN | 766 | 0.93 | 0.57 | 38085 |
| 2026-04-24 | REGN | 751.28 | 0.94 | 1.06 | 39620 |
| 2026-04-27 | REGN | 744.51 | 0.90 | 2.10 | 39203 |
| 2026-04-28 | REGN | 731.94 | 0.93 | 1.49 | 40649 |
| 2026-04-29 | REGN | 687.5 | 0.95 | 0.61 | 43155 |
| 2026-04-30 | REGN | 706.81 | 0.98 | 0.57 | 43934 |
| 2026-05-01 | REGN | 701.12 | 0.97 | 0.93 | 44680 |
| 2026-05-04 | REGN | 709.48 | 1.00 | 0.63 | 41363 |
| 2026-05-05 | REGN | 702.33 | 1.00 | 0.73 | 41882 |
| 2026-05-06 | REGN | 720.84 | 1.00 | 1.18 | 42395 |
| 2026-05-07 | REGN | 709.11 | 1.01 | 1.54 | 43251 |
| 2026-05-08 | REGN | 714.88 | 1.02 | 1.10 | 43950 |
| 2026-05-11 | REGN | 712.77 | 1.00 | 1.80 | 43005 |
| 2026-05-12 | REGN | 723.12 | 1.02 | 2.13 | 43727 |
| 2026-05-13 | REGN | 719.88 | 1.05 | 1.19 | 44595 |
| 2026-05-14 | REGN | 712.51 | 1.04 | 3.71 | 45486 |
| 2026-05-15 | REGN | 698.77 | 1.05 | 0.86 | 45827 |
| 2026-05-18 | REGN | 629.35 | 1.08 | 1.23 | 38602 |
| 2026-05-19 | REGN | 630.29 | 1.14 | 0.70 | 41584 |
| 2026-05-20 | REGN | 649.8 | 1.12 | 0.53 | 43074 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-21 | REGN | 747.40 | 8.0 | -1587.3 | 44.93 |
| 2026-04-22 | REGN | 746.96 | 8.0 | -1578.7 | 44.91 |
| 2026-04-23 | REGN | 766.24 | 8.0 | -1471.3 | 44.91 |
| 2026-04-24 | REGN | 751.47 | 8.0 | -1652.3 | 44.91 |
| 2026-04-27 | REGN | 744.61 | 7.5 | -1613.6 | 45.15 |
| 2026-04-28 | REGN | 731.77 | 8.3 | -1644.6 | 45.21 |
| 2026-04-30 | REGN | 707.15 | 8.3 | -1445.9 | 45.21 |
| 2026-05-01 | REGN | 701.46 | 8.3 | -1538.8 | 45.21 |
| 2026-05-04 | REGN | 709.45 | -16.2 | -1442.1 | 46.49 |
| 2026-05-05 | REGN | 702.34 | -15.6 | -1527.7 | 46.54 |
| 2026-05-06 | REGN | 721.08 | -15.6 | -1380.5 | 46.54 |
| 2026-05-07 | REGN | 708.97 | -15.5 | -1556.1 | 46.37 |
| 2026-05-08 | REGN | 714.68 | -15.5 | -1456.6 | 46.37 |
| 2026-05-11 | REGN | 712.72 | -15.5 | -1500.7 | 46.37 |
| 2026-05-12 | REGN | 723.45 | -15.8 | -1427.9 | 46.50 |
| 2026-05-13 | REGN | 719.78 | -15.8 | -1508.7 | 46.50 |
| 2026-05-14 | REGN | 712.57 | -15.8 | -1445.5 | 46.50 |
| 2026-05-15 | REGN | 698.22 | -15.8 | -1488.5 | 46.50 |
| 2026-05-18 | REGN | 629.67 | -15.8 | -1810.5 | 46.50 |
| 2026-05-19 | REGN | 630.66 | -15.8 | -1397.0 | 46.50 |
| 2026-05-20 | REGN | 649.67 | -15.8 | -1274.8 | 46.50 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-21 | REGN | -0.33 | 0.96 | 2.50 |
| 2026-04-22 | REGN | -0.33 | 0.96 | 2.50 |
| 2026-04-23 | REGN | -0.33 | 0.96 | 2.50 |
| 2026-04-24 | REGN | -0.33 | 0.96 | 2.50 |
| 2026-04-27 | REGN | -0.33 | 1.02 | 2.79 |
| 2026-04-28 | REGN | -0.33 | 1.02 | 2.79 |
| 2026-04-29 | REGN | -0.33 | 1.02 | 2.79 |
| 2026-04-30 | REGN | -0.33 | 1.02 | 2.79 |
| 2026-05-01 | REGN | -0.17 | 1.02 | 2.79 |
| 2026-05-04 | REGN | -0.17 | 0.66 | 2.82 |
| 2026-05-05 | REGN | -0.17 | 0.66 | 2.82 |
| 2026-05-06 | REGN | -0.17 | 0.66 | 2.82 |
| 2026-05-07 | REGN | -0.17 | 0.66 | 2.82 |
| 2026-05-08 | REGN | -0.17 | 0.66 | 2.82 |
| 2026-05-11 | REGN | -0.16 | 0.59 | 2.82 |
| 2026-05-12 | REGN | -0.16 | 0.59 | 3.24 |
| 2026-05-13 | REGN | -0.16 | 0.59 | 3.24 |
| 2026-05-14 | REGN | -0.16 | 0.59 | 3.24 |
| 2026-05-15 | REGN | -0.16 | 0.59 | 3.24 |
| 2026-05-18 | REGN | -0.16 | -0.77 | 3.24 |
| 2026-05-19 | REGN | -0.16 | -0.77 | 3.24 |
| 2026-05-20 | REGN | -0.16 | -0.77 | 3.24 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
9.47
Avg. EPS Est. Current Quarter
10.86
Avg. EPS Est. Next Quarter
13.09
Insider Transactions
-0.16
Institutional Transactions
-0.77
Beta
0.29
Average Sales Estimate Current Quarter
3814
Average Sales Estimate Next Quarter
4190
Fair Value
720.36
Quality Score
98
Growth Score
80
Sentiment Score
7
Actual DrawDown %
46.4
Max Drawdown 5-Year %
-59.7
Target Price
838.23
P/E
15.83
Forward P/E
12
PEG
1.07
P/S
4.57
P/B
2.17
P/Free Cash Flow
16.56
EPS
41.04
Average EPS Est. Cur. Y​
46.5
EPS Next Y. (Est.)
48.2
Target Price Estimates Raised
Target Price Estimates Lowered
14
Profit Margin
29.65
Relative Volume
1.54
Return on Equity vs Sector %
-12.9
Return on Equity vs Industry %
2.6
EPS 1 7Days Diff
EPS 1 30Days Diff
1.46
EBIT Estimation
-1274.8
â—†
REGN
Healthcare
$649.76
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
33.6
Range 1M
22.6%
Sup Dist
5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
4.9%
EPS NY
16.6%
52W%
49.2%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+88.9% upside
Upside
+88.9%
Quality
98
MoS
11%
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15343
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
REGN
Latest News
—
Caricamento notizie per REGN…
stock quote shares REGNÂ – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGNÂ – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGNÂ – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGNÂ – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading